Stevanato Group (STVN) Q2 2026 earnings review
Solid HVS Growth Masks Bottom-Line Hit from Balda Divestiture
Stevanato delivered steady Q2 results with total revenue growing 8% YoY to €302M, fueled by a 16% surge in High-Value Solutions (HVS) driven by robust GLP-1 and biologic demand. However, reported Net Income dropped sharply by 23% to €23M. This bottom-line optical deterioration was heavily distorted by a €12.2M one-time loss from divesting the non-core Balda C. Brewer subsidiary, alongside a spiked 39.8% tax rate. Looking past the divestiture noise, underlying operations are strong: Adjusted EBITDA margin expanded 280 bps to 26.0% and the Engineering segment successfully reversed its unprofitability. Management refined FY26 guidance, absorbing the €15M H2 revenue loss from Balda by projecting stronger organic growth in the core business.
🐂 Bull Case
The Engineering segment flipped from an operating loss last year (-0.8%) to a 2.9% operating profit, proving that the ongoing business optimization plan and right-sizing efforts in Denmark are bearing fruit.
Regulatory approval in Europe for the proprietary Alina pen injector platform validates Stevanato's 8-year investment to move up the value chain from pure component supplier to integrated device provider.
🐻 Bear Case
Despite a massive 16.4% jump in HVS revenue, BDS segment gross margin actually compressed by 10 bps YoY due to the drag of heavy depreciation from new facility ramp-ups and rising utility costs.
The expiration of Italy's IRES premiale tax break structurally raised the tax rate, while ongoing U.S. reciprocal tariffs continue to pressure costs despite targeted pricing actions.
⚖️ Verdict: ⚪
Neutral to Slightly Bullish. The core thesis—transitioning to high-value proprietary biologic solutions—remains perfectly intact and is accelerating. However, near-term financials are messy due to divestitures, capacity ramp costs, and tax rate normalization.
Key Themes
Alina Pen Platform Receives Critical Approval
Stevanato secured a major regulatory approval in Europe for a liraglutide-based therapy incorporating its proprietary Alina variable dose pen platform. This marks the culmination of an 8-year development cycle and officially transitions the company into the highly lucrative, integrated drug delivery systems market. Management explicitly noted this validation will de-risk the platform for other prudent pharmaceutical clients and expects it to generate double-digit revenue growth in the coming years.
HVS Mix Shift Accelerating on GLP-1 Demand
The shift toward High-Value Solutions is stable and robust. HVS revenue grew 16.4% YoY in Q2, reaching 45% of total revenue. GLP-1 related products now account for roughly 22% to 23% of the company's entire top line. Management is expanding capacity for Alba and Nexa syringes specifically to meet this unabated demand from both originators and the impending wave of biosimilars.
Engineering Profitability Reversing Upward
After quarters of dragging down consolidated results, the Engineering segment's financial profile is reversing. The optimization plan yielded a massive 540 bps expansion in gross margin (to 12.0%) and flipped the operating margin from negative 0.8% in 25Q2 to positive 2.9% in 26Q2. This was achieved through better project mix and reducing losses at the Danish operations.
BDS Gross Margin Contradicts HVS Growth Narrative
A concerning data point emerged: BDS segment gross margin contracted by 10 bps YoY to 31.1%, despite a 16.4% surge in highly profitable HVS revenue. The positive mix shift was fully offset by the heavy depreciation burden from newly installed lines at the Fishers and Latina plants, alongside rising utility costs. Until these facilities scale to higher utilization, they will act as a structural anchor on gross margin expansion.
Balda Divestiture Causes EPS and Tax Shock
The sale of the non-core Balda C. Brewer subsidiary resulted in a €12.2M one-time loss. Because this loss was non-deductible for tax purposes, and the company simultaneously lost Italy's 'IRES premiale' tax incentive, the Q2 effective tax rate spiked dramatically to 39.8% (up from 24.1% a year ago). While the divestiture removes a low-margin drag, the immediate optical impact on reported Net Income was severe.
Macro Headwinds: US Tariffs and FX
The company continues to battle macro headwinds. New reciprocal import tariffs imposed by the U.S. government in early 2026 increased material costs and tempered operating margins, as targeted pricing actions only partially offset the impact. Additionally, currency translation (primarily a weaker US Dollar earlier in the period) represented an approximate €10M top-line headwind for the first half of the year.
Engineering Sales Cycles Remain Elongated
Despite the margin turnaround, Engineering segment revenue decelerated, falling 2.0% YoY. Management noted that while the pipeline is rich, the sales cycle for converting opportunities into firm CapEx orders has noticeably lengthened as pharmaceutical customers deploy more disciplined procurement processes.
Other KPIs
Reversing. FCF deteriorated from -€13.0M a year ago. The cash burn is primarily driven by aggressive CapEx deployment (€52.0M in the quarter) to fund the Fishers and Latina capacity expansions, combined with working capital absorption from higher inventory levels to support upcoming launches.
Accelerating. Up 21% YoY, with Adjusted EBITDA margins expanding 280 bps to 26.0%. This highlights the underlying cash-generation power of the business when stripping out the Balda divestiture loss and restructuring charges.
Guidance
Stable. The range was narrowed from the previous €1.260 - €1.290 billion. Management absorbed the loss of ~€15M in H2 revenue from the Balda divestiture by modeling stronger organic growth and slightly more favorable FX, demonstrating confidence in core operations.
Accelerating. Adjusted upward from the prior range of €331.8 - €346.9 million. The divestiture of Balda is expected to be accretive to full-year margins, supporting a midpoint EBITDA margin target of 26.8%, up 170 bps from FY25.
Stable. Narrowed from the prior €0.59 - €0.63. The higher expected tax rate (now guided to ~28.2% adjusted) is being successfully offset by lower-than-anticipated depreciation and financial expenses.
Key Questions
Margin Drag from New Capacity
BDS gross margins contracted despite a 16% surge in HVS revenue, driven by depreciation from new lines. At what utilization rate will the Fishers and Latina facilities flip from being margin-dilutive to margin-accretive?
Tax Rate Normalization
With the expiration of the IRES premiale tax benefit and the Q2 spike to 39.8%, what is a normalized, long-term effective tax rate expectation for the group heading into FY27?
Future Divestitures
The Balda sale signals a clear shift away from standard diagnostics. Are there other non-core product lines or facilities currently under strategic review for divestiture to further concentrate capital on biologics?